Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.63 |
| ▸ | BRS3 | P32247 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443815 | 0.92 | RAB9A (0.59) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10578851 | 0.86 | BRS3 (0.74) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8126566 | 0.84 | BRS3 (0.58) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL30053816 | 0.82 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL106519 | 0.82 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL929012 | 0.82 | BRS3 (0.55) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8502565 | 0.82 | BRS3 (0.57) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14223570 | 0.82 | BRS3 (0.55) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9527448 | 0.81 | BRS3 (0.68) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1680900 | 0.81 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4628098-A | Including Prevacid (TM) lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)-5-methyl-pyrid-2 -yl)methylsulfinylbenzimidazole; proton pump inhibitors, antiulcer, antisecretory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-12-09 | — | — | US | claimed |
| US-10787651-B2 | Bradyrhizobium monooxygenase and use thereof for preparation of chiral sulfoxide | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2020-09-29 | — | — | US | disclosed |
| US-20200140830-A1 | BRADYRHIZOBIUM MONOOXYGENASE AND USE THEREOF FOR PREPARATION OF CHIRAL SULFOXIDE | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | RAB9A 2407/4885NPC1 646/4885CYP1A2 230/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | RAB9A 561/4885NPC1 1315/4885CYP1A2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.